new.firstwordpharma.com
Open in
urlscan Pro
84.207.240.117
Public Scan
Submitted URL: http://beta.firstwordpharma.com/
Effective URL: https://new.firstwordpharma.com/
Submission: On October 24 via api from QA — Scanned from DE
Effective URL: https://new.firstwordpharma.com/
Submission: On October 24 via api from QA — Scanned from DE
Form analysis 1 forms found in the DOM
<form class="NewsletterSignUpForm_form__31Vnj">
<h3 class="Typography_section-heading__1k1-w NewsletterSignUpForm_title__2iyOE">Interested <span class="NewsletterSignUpForm_avoidWrap__1GzNi">in other news?</span></h3>
<p class="Typography_body1__2a2SC Typography_gutter__24emn Typography_paragraph__29mPJ NewsletterSignUpForm_cta__1HUJI">Sign up to other FirstWord newsletters</p>
<div class="NewsletterSignUpForm_checkboxes__JLSXc">
<div class="SwitchBaseModern_checkboxParent__UGhlo className"><input id="interests[Biosimilars]" name="interests[Biosimilars]" type="checkbox" class="SwitchBaseModern_checkboxInput__1EU0u" value=""><span
class="SwitchBaseModern_checkboxMaterial__i5756"><span class="SwitchBaseModern_checkboxChecker__vpZdX"></span></span>
<div class="Ripple_rippleParent__9Ib8O SwitchBaseModern_ripple__3x5n9">
<div style="position: relative;">
<div class="Ripple_ripple__3jiXS" style="top: 0px; left: 0px;"></div>
</div><label for="interests[Biosimilars]" class="SwitchBaseModern_checkboxLabel__ZEPHe SwitchBaseModern_checkboxLeft__1aUeq">Biosimilars</label>
</div>
<div class="checkboxOff"></div>
</div>
<div class="SwitchBaseModern_checkboxParent__UGhlo className"><input id="interests[Medical Affairs]" name="interests[Medical Affairs]" type="checkbox" class="SwitchBaseModern_checkboxInput__1EU0u" value=""><span
class="SwitchBaseModern_checkboxMaterial__i5756"><span class="SwitchBaseModern_checkboxChecker__vpZdX"></span></span>
<div class="Ripple_rippleParent__9Ib8O SwitchBaseModern_ripple__3x5n9">
<div style="position: relative;">
<div class="Ripple_ripple__3jiXS" style="top: 0px; left: 0px;"></div>
</div><label for="interests[Medical Affairs]" class="SwitchBaseModern_checkboxLabel__ZEPHe SwitchBaseModern_checkboxLeft__1aUeq">Medical Affairs</label>
</div>
<div class="checkboxOff"></div>
</div>
<div class="SwitchBaseModern_checkboxParent__UGhlo className"><input id="interests[Most Read]" name="interests[Most Read]" type="checkbox" class="SwitchBaseModern_checkboxInput__1EU0u" value=""><span
class="SwitchBaseModern_checkboxMaterial__i5756"><span class="SwitchBaseModern_checkboxChecker__vpZdX"></span></span>
<div class="Ripple_rippleParent__9Ib8O SwitchBaseModern_ripple__3x5n9">
<div style="position: relative;">
<div class="Ripple_ripple__3jiXS" style="top: 0px; left: 0px;"></div>
</div><label for="interests[Most Read]" class="SwitchBaseModern_checkboxLabel__ZEPHe SwitchBaseModern_checkboxLeft__1aUeq">Most Read</label>
</div>
<div class="checkboxOff"></div>
</div>
<div class="SwitchBaseModern_checkboxParent__UGhlo className"><input id="interests[Oncology]" name="interests[Oncology]" type="checkbox" class="SwitchBaseModern_checkboxInput__1EU0u" value=""><span
class="SwitchBaseModern_checkboxMaterial__i5756"><span class="SwitchBaseModern_checkboxChecker__vpZdX"></span></span>
<div class="Ripple_rippleParent__9Ib8O SwitchBaseModern_ripple__3x5n9">
<div style="position: relative;">
<div class="Ripple_ripple__3jiXS" style="top: 0px; left: 0px;"></div>
</div><label for="interests[Oncology]" class="SwitchBaseModern_checkboxLabel__ZEPHe SwitchBaseModern_checkboxLeft__1aUeq">Oncology</label>
</div>
<div class="checkboxOff"></div>
</div>
</div>
<div>
<div class="InputTraditional_container__CnGyi">
<div class="FieldTraditional_inputContainer__3Fj8w"><input id="email" type="email" name="email" placeholder="Email Address" class="FieldTraditional_input__2HXY2" value=""></div>
</div>
</div>
<div class="Ripple_rippleParent__9Ib8O Button_raised__p5CsR NewsletterSignUpForm_button__3vUsW">
<div style="position: relative;">
<div class="Ripple_ripple__3jiXS" style="top: 0px; left: 0px;"></div>
</div><button type="submit" aria-label="Submit" class="Button_button__1tMRC Button_secondary__3aDiX"><span class="Button_title__3ZNhO"><span class="Typography_button__1Sf4d Typography_center__2qAqN Typography_inherit__2GCZn Button_text__3ipTN"
style="text-transform: none;">Sign up</span></span></button>
</div>
<a class="ViewMoreLink_link__3ghAQ NewsletterSignUpForm_link__3i_PV" href="/newsletters"><span class="ViewMoreLink_text__380Hq">View more Newsletters</span><svg width="24" height="24" class="Icon_svg__2fNPT ViewMoreLink_icon__1mVsk Icon_secondary__1IHL3" icon="svg/material-design-icons/hardware/keyboard_arrow_right" viewBox="0 0 24 24"><path d="M8.59 16.34l4.58-4.59-4.58-4.59L10 5.75l6 6-6 6z"></path></svg></a>
</form>Text Content
You need to enable JavaScript to run this app.
Sign In
Register
Contact Us
Home
News
* MyFW+ Stories
* Top Stories
* Product
* Company
* Regulatory
* Condition
* Business Area
* Conference
* People
* All News
Insight, Analysis & Views
* KOL Views
* Physician Views
* FirstImpact
* ViewPoints
* In The Know
* Friday Five
* All IAV
StoryWatch
* Biosimilars
* Coronavirus
* Deals - Alliances - Financing
* Emerging Markets
* FDA AdCom Tracker
* Gene/Car-T Cell Therapy
* Health Meets Tech
* Latest Earnings Reports
* Market Access Issues
* Orphan Drugs
* Product Approvals
* Trump Tackles Drug Prices
More
* Intelligence Reports
* Newsletters
* FirstAnswers
* What's New?
* About FirstWord
* Advertise with Us
FIRSTWORD PHARMA
* MyFW+
* News
* Insight, Analysis & Views
*
* Register
* Sign In
PFIZER, BIONTECH'S COVID-19 BOOSTER YIELDS 95.6% EFFICACY
Comirnaty boosters were recently authorised for emergency use in the US for
older individuals and others deemed to be at higher risk.
2 days ago
TOP STORIES
Top Story
ROCHE'S SUSVIMO EYE IMPLANT GETS US NOD FOR WET AMD
Company says Susvimo becomes the first wet AMD treatment in 15 years to provide
an alternative to standard eye injections needed as often as once a month.
29 hours ago
Top Story
PFIZER, BIONTECH SAY COMIRNATY 90.7% EFFECTIVE IN YOUNG CHILDREN
The FDA is expected to soon release its own evaluation of data on the COVID-19
vaccine's safety and effectiveness among five- to 11-year-olds.
36 hours ago
Top Story
AGENUS SHARES SLIDE AFTER PULLING CERVICAL CANCER FILING FOR BALSTILIMAB
Company voluntarily withdraws application for PD-1 inhibitor at FDA's
recommendation following recent full approval of Merck & Co.'s Keytruda in
certain cervical cancer patients.
36 hours ago
Top Story
EU APPROVES KEYTRUDA FOR TRIPLE-NEGATIVE BREAST CANCER
Merck & Co. noted that the decision represents the anti-PD-1 therapy's first
approval in Europe in a breast cancer setting.
37 hours ago
Top Story
DUPIXENT HITS MAIN GOAL IN PHASE III CHRONIC ITCH TRIAL
Sanofi and Regeneron said 37% of prurigo nodularis patients given the IL-4/IL-13
inhibitor experienced a clinically meaningful reduction in itch at week 12,
versus 22% for placebo.
38 hours ago
View More Top Stories
RECOMMENDED FOR YOU
Register in order to benefit from FirstWord Pharma's recommendation technology
helping you discover news and content of interest to you.
CONFERENCE NEWS
Conference Dispatch
ADDITION OF GNRH AGONIST DOES NOT INCREASE LIVE BIRTH RATES DURING EMBRYO
TRANSFER: PRESENTED AT ASRM
By Louise Gagnon VIRTUAL -- October 22, 2021 -- The use of a GnRH agonist
(GnRHa) at the time of embryo transfer, either fresh or frozen, did not result
in a significant difference in live birth rate...
28 hours ago
Conference Dispatch
EXPOSURE OF OVARIES TO COVID-19 VACCINATION DOES NOT IMPAIR FERTILITY: PRESENTED
AT ASRM
By Louise Gagnon VIRTUAL -- October 22, 2021 -- Embryos produced from oocytes
exposed in vivo to lipid nanoparticles containing mRNA for the severe acute
respiratory syndrome coronavirus 2 (SARS CoV-...
28 hours ago
Conference Dispatch
ONABOTULINUMTOXINA PROVIDES RELIEF FROM PERSISTENT PELVIC PAIN IN PATIENTS WITH
ENDOMETRIOSIS: PRESENTED AT ASRM
By Louise Gagnon VIRTUAL -- October 22, 2021 -- Injecting onabotulinumtoxinA
into pelvic floor muscles with spasms provided pain relief in women with
endometriosis-related chronic pain refractory to...
28 hours ago
Conference Dispatch
BARIATRIC SURGERY IMPROVES RISKS OF HYPERTENSIVE DISORDERS OF PREGNANCY,
GESTATIONAL DIABETES IN OBESE WOMEN WITH PCOS: PRESENTED AT ASRM
By Louise Gagnon VIRTUAL -- October 22, 2021 -- Weight loss achieved with
bariatric surgery in obese women with polycystic ovarian syndrome (PCOS) was
associated with a decreased risk of pregnancy-in...
29 hours ago
Conference Dispatch
PARADOXICAL BRONCHOSPASM UNDER-RECOGNISED AMONG PATIENTS HAVING SPIROMETRY
TESTS: PRESENTED AT CHEST
By Ed Susman VIRTUAL -- October 22, 2021 -- Patients diagnosed with asthma or
chronic obstructive pulmonary disease (COPD) undergoing spirometry testing may
exhibit a rare paradoxical bronchospasm --...
32 hours ago
View More Conference News
RECENT REPORTS
FWReports
PANCREATIC CANCER -- KOL INSIGHT
There is unmet need across all stages of pancreatic cancer therapy. Merck &
Co’s Keytruda and AstraZeneca’s Lynparza offer benefit to only a minority of
patients and chemotherapy remains the...
FWReports
PANCREATIC CANCER -- KOL INSIGHT -- REPORT HIGHLIGHTS
There is unmet need across all stages of pancreatic cancer therapy. Merck &
Co’s Keytruda and AstraZeneca’s Lynparza offer benefit to only a minority of
patients and chemotherapy remains the...
FWReports
MELANOMA -- KOL INSIGHT
What underpins KOLs’ opinion that BMS’ Opdivo in combination with low-dose
Yervoy could be revolutionary in the neo-adjuvant setting? What clinical trial
readouts lead experts to believe Merck & C...
FWReports
MEDICAL AFFAIRS REPUTATIONS (UK) -- ASTHMA/COPD (INHALABLES)
According to this latest survey of 30 UK pulmonologists and allergists, the
performance of asthma/COPD medical affairs teams for some high profile brands
still has a way to go in some key areas. Find ...
FWReports
MEDICAL AFFAIRS REPUTATIONS (IT) -- ASTHMA/COPD (INHALABLES)
According to this latest survey of 30 Italian pulmonologists and allergists, the
performance of asthma/COPD medical affairs teams for some high profile brands
still has a way to go in some key areas. ...
View More Reports
INSIGHT, ANALYSIS & VIEWS
ViewPointsPLUS
VIEWPOINTS: FDA PROVIDES GUIDANCE ON SOURCING AND SUBMITTING REAL-WORLD DATA TO
SUPPORT DRUG APPROVALS
Physician Views
PHYSICIAN VIEWS: WHAT IMPACT FROM BIOSIMILAR LUCENTIS?
ViewPointsPLUS
VIEWPOINTS: ELACESTRANT HERALDS THE ARRIVAL OF ORAL SERDS
ViewPoints
THE FIRST TAKE – BIOGEN BANKS ON MEDICARE DECISION TO RESCUE ADUHELM
ViewPointsPLUS
VIEWPOINTS: BIOMARKER TESTING WILL SLOW BUT NOT PREVENT EARLY-STAGE OF USE OF
ELI LILLY’S VERZENIO
View More Insight, Analysis & Views
INTERESTED IN OTHER NEWS?
Sign up to other FirstWord newsletters
Biosimilars
Medical Affairs
Most Read
Oncology
Sign up
View more Newsletters
© 2021 FirstWord. All rights reserved
|
1140 Avenue of the Americas, 14th Floor, New York, NY 10036
About FirstWord|Advertise With Us|Contact Us|Privacy Policy
×
We Value Your Privacy
Settings
NextRoll, Inc. ("NextRoll") and our advertising partners use cookies and similar
technologies on this site and around the web to collect and use personal data
(e.g., your IP address). If you consent, the cookies, device identifiers, or
other information can be stored or accessed on your device for the purposes
described below. You can click "Allow All" or "Decline All" or click Settings
above to customize your consent.
NextRoll and our advertising partners process personal data to: ● Store and/or
access information on a device; ● Create a personalized content profile; ●
Select personalised content; ● Personalized ads, ad measurement and audience
insights; ● Product development. For some of the purposes above, our advertising
partners: ● Use precise geolocation data. Some of our partners rely on their
legitimate business interests to process personal data. View our advertising
partners to see the purposes they believe they have a legitimate interest for
and how you can object to such processing.
Your changes on this site will be applied across the internet on any digital
property you visit using NextRoll's technology. If you select Decline All, you
will still be able to view content on this site and you will still receive
advertising, but the advertising will not be tailored for you. You may change
your setting whenever you see
Decline All
Allow All